Michigan doctor warns of rising flu cases this season

CDC data show at least 7.2 million U.S. flu cases this season as of Dec. 20, with Michigan experiencing a 'very high' influenza‑like illness level and atypically early spikes. Local clinicians attribute the surge to an H3N2 K subclade not well matched by this season’s vaccine, raising risks of higher hospitalizations—particularly among those over 65 and young children—and increased pneumonia cases; clinicians recommend vaccination and basic infection controls. For investors, the development implies modest near‑term upside pressure on demand for vaccines, antivirals and hospital services and potential staffing/operational strain at regional health providers, but it does not currently represent a broad market‑moving event.

Analysis

Market structure: Early-season H3N2 activity shifts near-term demand toward vaccines, rapid diagnostics, antivirals and outpatient/retail vaccination channels. Expect 5–15% sequential revenue bumps over 1–3 months for point-of-care test makers and pharmacy vaccination services if CDC weekly ILI stays in “very high” for >2 consecutive weeks; elective care and travel-exposed sectors should see offsetting weakness. Pricing power will be limited for vaccines this season (supply largely contracted), while diagnostic makers with rapid-test capacity can reprice via volume and urgency channels.

Risk assessment: Tail risks include a larger-than-expected virulent wave driving localized hospital stress, temporary capacity-driven rationing, or regulatory action (stockpiling, export controls) within 30–90 days; low-probability but high-impact. Immediate (days) effects are volume and OTC sales; short-term (weeks/months) are hospital utilization and insurer medical-loss ratios; long-term (quarters) could accelerate adoption of next-gen influenza vaccines (mRNA) if mismatch persists. Hidden dependencies include state-level vaccine procurement, school closure policies, and IV antiviral supply chains.

Trade implications: Favor diagnostics, retail pharmacy vaccination channels, and antiviral suppliers; avoid travel/leisure and selectively hedge insurers. Prefer trade structures that capture near-term spikes in demand (1–3 month exposures) while limiting duration into Q2 when seasonality fades. Use options to express asymmetric risk: buy calls on diagnostic/pharmacy names and buy short-dated puts on airlines; consider pairs to isolate flu exposure from broader health care beta.

Contrarian: Consensus underestimates the speed at which outpatient channels capture displaced hospital demand — retail clinics (CVS/WBA) will monetize vaccinations and antivirals quickly while hospitals absorb severe cases. Reaction may be underdone for diagnostics (market still focused on COVID tests); vaccine manufacturers may be overvalued for immediate benefit because current vaccines are mismatched. Historical parallels (mismatched H3N2 seasons) show concentrated 6–10 week revenue spikes rather than sustained multi-quarter growth, arguing for short-term tactical trades rather than long-term buys.

Key Decisions for Investors

• Establish a 2–3% long position in Abbott Laboratories (ABT) via a 3-month call spread: buy ABT 3-month 10% OTM calls and sell 20% OTM calls to limit cost—thesis: rapid-test volume + 5–15% revenue bump if ILI remains high for 2+ weeks; exit if ABT up 20% or CDC ILI drops below 'moderate' for 2 consecutive weeks.
• Establish a 2% long position in CVS Health (CVS) common stock to capture vaccine administration and OTC sales; add if weekly vaccination counts reported by CDC/yield data show >10% YoY increase over baseline; trim on +15% move or after March 31, 2026 (seasonality end).
• Buy 1–2% notional short exposure to US airlines (AAL or UAL): purchase 1–2 month 7.5–10% OTM puts sized to ~1–2% portfolio risk, given near-term travel softness risk; close if airline volumes recover to seasonally normal levels or if government advisories do not change within 30 days.
• Pair trade: Long diagnostics (ABT) 2% vs short insurers (UNH) 1% — rationale: diagnostics upside from volume spike vs insurers’ marginally higher medical-loss ratios; unwind pair if MLR impact is <1 percentage point on UNH quarterly guidance.
• For aggressive directional: 1% position in Moderna (MRNA) or BioNTech (BNTX) via 6–12 month LEAP calls (buy) only if continued vaccine mismatch reports persist into Feb–Mar 2026, signaling accelerated demand for next-gen mRNA flu programs; cap exposure to 1% because upside is binary and longer-horizon.